KalVista skyrockets following data from KVD900 trial demonstrating efficacy Check out this morning's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- KalVista (KALV) up 142% after announcing topline data from a Phase 2 clinical trial demonstrating statistically and clinically significant efficacy of KVD900 as an oral on-demand treatment for hereditary angioedema attacks
- Heat Biologics (HTBX) up 124% after
announcing interim data of the company's Phase 2 trial of HS-110, in combination with Bristol-Myers' (BMY) Opdivo, in advanced non-small cell lung cancer
- Tilray (TLRY) up 16% after announcing it has established an agreement with Grow Pharma to import and distribute Tilray's medical cannabis products into the United Kingdom
- Glu Mobile (GLUU) up 33% after the company's announcement that it is being acquired by Electronic Arts (EA) for $2.1B in enterprise value, or $12.50 in cash per share
UP AFTER EARNINGS -
- S&P Global (SPGI) up 2%
- Incyte (INCY) up 1%
- Aramark (ARMK) up 4%
- II-VI (IIIVI) up 5%
- Hanesbrands (HBI) up 4%
DOWN AFTER EARNINGS -
- FIS (FIS) down 1%
- Centene (CNC) down 1%
- Coty (COTY) down 4%
- Take-Two (TTWO) down 4%
LOWER -
- Ekso Bionics (EKSO) down 20% after 3.902M share spot secondary priced at $10.25
- Cleveland-Cliffs (CLF) down 9% after 60M share spot secondary priced at $16.29
Symbols:
KALV TLRY HTBX SPGI - $325.31 /
+1.315 (+0.41%)
INCY ARMK IIVI HBI CNC COTY TTWO - $213.30 /
+5.925 (+2.86%)
EKSO CLF FIS BMY GLUU EA Keywords: Fly Intel, Wall Street, Top Stories, Stocks